-
Please note that signing in with a Display Name has been removed. Email addresses must be used instead to login.
Learning Center
Share information related to IT Technologies
3,178 topics in this forum
-
- 0 replies
- 343 views
-
- onlineandhra
-
-
- 0 replies
- 390 views
-
- onlineandhra
-
- 0 replies
- 326 views
-
- onlineandhra
-
- 0 replies
- 322 views
-
- onlineandhra
-
- 0 replies
- 449 views
-
- onlineandhra
-
- 0 replies
- 346 views
-
- onlineandhra
-
- 0 replies
- 382 views
-
- onlineandhra
-
- 0 replies
- 336 views
-
- onlineandhra
-
- 0 replies
- 361 views
-
- onlineandhra
-
- 0 replies
- 339 views
-
- onlineandhra
-
- 0 replies
- 345 views
-
- onlineandhra
-
- 0 replies
- 326 views
-
- onlineandhra
-
- 0 replies
- 520 views
-
- Neeharika1
-
- 0 replies
- 400 views
-
- johnweetly
-
- 0 replies
- 360 views
-
- onlineandhra
-
- 0 replies
- 331 views
-
- onlineandhra
-
- 0 replies
- 365 views
-
- onlineandhra
-
- 0 replies
- 348 views
-
- onlineandhra
-
- 0 replies
- 332 views
-
- onlineandhra
-
- 0 replies
- 300 views
-
- onlineandhra
-
- 0 replies
- 305 views
-
- onlineandhra
-
- 0 replies
- 324 views
-
- onlineandhra
-
- 0 replies
- 303 views
-
- onlineandhra
-
- 0 replies
- 304 views
-
- onlineandhra
-
- 0 replies
- 339 views
-
- onlineandhra
-
-
-
-
Popular Contributors
-
1
johnydanylee
387 -
2
DallasKarreballu
127 -
3
psycopk
100 -
4
Sucker
85 -
5
Android_Halwa
74
-
-
-
Most Contributions
-
Methrencet
507477 -
Spartan
180698 -
psycopk
142354 -
k2s
114199 -
mustang302
108516
-
-
-
Activity Stream
-
79
farmers are voluntarily coming forward to give their lands, Amaravati Second phase
Wait cheye bhaya, #musali_sintakaya_cheeketoda #musalodi_m0ddagudese vadu vachi reply estadu. arey @Sinthakai, ekkada chachavu ra bhaya waiting. -
2
Permanent cure for male-pattern baldness.Cosmo has released its Phase III trial results
https://www.cosmopharma.com/news/cosmo-announces-breakthrough-phase-iii-topline-results-from-scalp-1-and-scalp-2-for-clascoterone-5-solution-in-male-hair-loss-showing-up-to-539-relative-improvement-in-target-area-hair-count-vs-place Cosmo announces breakthrough Phase III Topline results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in male hair loss, showing up to 539% relative improvement in Target-Area Hair Count vs placebo; US and EU submissions are underway Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated across both studies Positive safety profile demonstrated across both studie Largest Phase III program ever conducted for a Topical Treatment for Male Androgenetic Alopecia (AGA) First novel mechanism of action and first potential innovation in over 30 years in male hair loss Preparations are underway for parallel regulatory submissions in the United States and Europe -
-
-
1
-
